Avimex

What Avimex does

Avimex (legal name LABORATORIO AVI-MEX, S.A. DE C.V.) is a privately held, 100% Mexican-capital biopharmaceutical company founded in 1952 and headquartered in Iztapalapa, Mexico City. The company conducts research, development, manufacturing, and commercialization of high-technology vaccines, pharmaceuticals, disinfectants, and specialized mycotoxin detoxificants for animal health across four segments: poultry, swine, cattle, and aquaculture. Its proprietary Vaxigen® vectorized vaccine line, built on the recombinant Newcastle Disease Virus (rNDV) platform licensed exclusively for Mexico from the Icahn School of Medicine at Mount Sinai, anchors a deep biological product portfolio, complemented by antibiotics (Fosfomycin, Norfloxacin, Enrofloxacin, Gentamicin), mycotoxin detoxificants (mycoad® ZT, myco-ad®), and disinfectants (bio-clean®). Production capacity exceeds 2,500 million vaccine doses per year for animals, supported by two dedicated R&D laboratories (Mexico City for field isolation and Querétaro for molecular biology / vectorized platforms) and BSL-3 containment facilities.

Avimex's go-to-market relies on an extensive third-party distributor network reaching 30+ countries across Latin America (Bolivia, Colombia, Ecuador, El Salvador, Guatemala, Honduras, Nicaragua, Peru, Dominican Republic, Trinidad & Tobago, Argentina, Uruguay, Chile via Phibro), Africa, Asia, and Oceania, supplemented by a direct website customer portal and the Avimex Courses professional development program. Quality is underpinned by ISO 9001:2015, government-issued Buenas Prácticas de Manufactura (BPM), and Buenas Prácticas de Laboratorio (BPL/GLP) certifications, plus COFEPRIS regulatory clearances. Pricing is not publicly disclosed and the company has no direct-to-consumer pricing surface, consistent with its channel-partner distribution model.

In 2020, Avimex expanded into human biopharmaceuticals by establishing a Biofarmacéutica division with pilot and industrial plants for 100% national production of recombinant vaccines, and by initiating the Patria® (AVX/COVID-12) COVID-19 vaccine in alliance with CONACyT, the Mexican federal government, UNAM, INER, IMSS, and Médica Sur. The project combined the Mount Sinai-licensed rNDV platform with the HexaPro spike protein licensed from the University of Texas at Austin. After Phase I (2021-2022) and Phase II (2022) advancements and a final-stage clinical development data drop in May 2023 showing neutralizing antibody levels comparable to a WHO-approved vaccine, Avimex is positioned to pursue industrialization of the Patria® candidate, while continuing to expand its veterinary Vaxigen® and Innovac® franchises. The company is family/founder-controlled with no public listing, no external institutional investors identified, and revenue is not publicly disclosed.

Name

Avimex

Legal name

LABORATORIO AVI-MEX, S.A. DE C.V.

Website

https://avimex.com.mx

Company type

Private

Founded year

1952

Operating status

Operating

Headcount range

101–250 employees

Short description

Avimex is a privately held, 100% Mexican-capital biopharmaceutical company founded in 1952 that develops, manufactures, and commercializes vaccines, pharmaceuticals, and mycotoxin detoxificants for poultry, swine, cattle, and aquaculture producers across 30+ countries, and is now expanding into human vaccines via the Patria® COVID-19 program.

Ownership category

akta.pro rank

Product category

Veterinary Animal Health Pharmaceuticals and Vaccines

SIC

Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAMAKAI

Vaccine Manufacturing & Contract Services (Veterinary Vaccine CDMO)

Healthcare & Life Sciences/Veterinary & Animal Health/Animal Vaccines

SECONDARYHLAMAEAN

Medicated Feed Additives & Premixes (Veterinary Pharmaceuticals)

Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics

SECONDARYAFADAKAG

Mycotoxin Risk Management (Binders, Deactivators)

Agriculture & Food Production/Animal Feed Manufacturing/Medicated & Functional Feed (Coccidiostats, Probiotics, Performance Additives)

SECONDARYHLAMAEAE

Antimicrobials & Anti-infectives

Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics

Keywords

• Animal health products
• Veterinary vaccines
• Animal pharmaceuticals
• Mycotoxin detoxificants
• Aquaculture health

Headquarters

HQ city

Mexico City

HQ country

Mexico

HQ region

Latin America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Animal Health Products: Research, development, manufacturing, import, export, and commercialization of high-technology vaccines, pharmaceuticals, disinfectants, and specialized mycotoxin detoxificants for animal health
2. Human Biopharmaceutical Products: Development and production of recombinant vaccines for human use through biopharmaceutical division established in 2020 with pilot and industrial plant facilities for 100% national production

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Avimex (Laboratorio Avi-Mex, S.A. de C.V.) researches, develops, manufactures, and commercializes high-technology veterinary vaccines, pharmaceuticals, disinfectants, and specialized mycotoxin detoxificants for the animal health sector. The portfolio serves four segments — poultry (Aves), swine (Cerdos), cattle (Bovinos), and aquaculture (Aqua) — with branded product lines such as Vaxigen®, Innovac®, Vaxsafe®, Newca-mex®, mycoad®, and bio-clean®, distributed via an extensive Latin American and international distributor network. Through a biopharmaceutical division established in 2020, the company also developed the Patria® (AVX/COVID-12) COVID-19 vaccine candidate for human use.

Product overview

Avimex® is a Mexican biopharmaceutical company founded in 1952 specializing in animal health products. The company offers a comprehensive portfolio across four market segments: poultry (Aves), swine (Cerdos), cattle (Bovinos), and aquaculture (Aqua). The product portfolio includes: (1) Vaccines - the flagship Vaxigen® line of vectorized vaccines for poultry including Vaxigen® newG5, Vaxigen® Flu H5N8, Vaxigen® new-ILT, and Newcastle-Infectious Bronchitis-Hepatitis-EDS combination vaccines; the Innovac® line for swine including Innovac® L-PRRS, Innovac® ip, and Innovac® ojo azul; plus Vaxsafe® vaccines; (2) Pharmaceuticals - antibiotic solutions including fx plus® (Fosfomycin), floxacin® (Norfloxacin), aviflox® (Enrofloxacin), genta-mex® (Gentamicin), magna-mix®, and mucosol® (mucolytic); (3) Detoxicants - mycoad® ZT and myco-ad® for mycotoxin detoxification; (4) Disinfectants - bio-clean® organic disinfectant; (5) Specialty products - virotón® for fighting roosters; (6) Aqua products - dermo-gard® AQUA, oxi-blend® AQUA, and flor-blend® AQUA. Additionally, Avimex has developed the Patria® COVID-19 vaccine candidate (AVX/COVID-12) for human use through its biopharmaceutical division.

Differentiator

Problem solved

Functional benefit

Products and services

• Vaxigen® newG5 Active recombinant vectorized vaccine for prevention of Newcastle disease in poultry.
• Vaxigen® Flu H5N8 Clade 2.3.4.4 High-efficacy vectorized vaccine against Highly Pathogenic Avian Influenza (HPAI) H5N1, Clade 2.3.4.4 for poultry.
• Vaxigen® new-ILT Active dual recombinant vectorized vaccine for prevention of Newcastle disease and Infectious Avian Laryngotracheitis in poultry.
• Vaxigen® Flu-H7 Reverse genetics inactivated vectorized vaccine for prevention of avian influenza subtype H7N3 in poultry.
• Vaxigen® K-newH5® Inactivated vectorized vaccine for prevention of avian influenza subtype H5 and Newcastle disease in poultry.
• Innovac® L-PRRS Vaccine against Porcine Reproductive and Respiratory Syndrome (PRRS) for swine operations.
• Vaxsafe® MHP Live attenuated vaccine for prevention of enzootic pneumonia caused by Mycoplasma hyopneumoniae in swine.
• Innovac® IP Inactivated vaccine for prevention of swine influenza in pork production operations.
• Innovac® Ojo Azul Inactivated vaccine for prevention of Blue Eye Disease in swine.
• Innovac® LaSota Active frozen vaccine for prevention of Newcastle disease in poultry.
• Vaxsafe® MS

Quantifiable outcome

• Production capacity of over 2,500 million vaccine doses per year for animals
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered major, flagship and core.

• UNAM (Universidad Nacional Autónoma de México)majorStrategic or Co-development Partner · 1 April 2021UNAM joined the Patria vaccine project providing analytical testing for vaccine characterization, interpretation of preclinical trial results, and support in clinical protocol design.
• INER (Instituto Nacional de Enfermedades Respiratorias)majorStrategic or Co-development Partner · 1 April 2021INER joined the Patria vaccine project to support with immunological analysis in human clinical trials, contributing talent and infrastructure.
• IMSS (Instituto Mexicano del Seguro Social)majorStrategic or Co-development Partner · 1 April 2021IMSS partnered for clinical trial phases, having previously collaborated successfully with Avimex in 2009 on an H1N1 influenza vaccine clinical trial during pandemic conditions.
• Médica Sur HospitalmajorStrategic or Co-development Partner · 1 April 2021Clinical trial site for Phase I of Patria vaccine with the highest standards for clinical research, supervised by independent CROs.
• CONACyT (Consejo Nacional de Ciencia y Tecnología)flagshipStrategic or Co-development Partner · 1 March 2020Primary government partner coordinating the Patria vaccine (AVX/COVID-12) development. CONACyT selected Avimex for the national vaccine project, providing financing, advisory services, and coordination of scientific committees and institutional collaborations. The alliance represents a major strategic initiative for Mexico's vaccine sovereignty.
• Icahn School of Medicine at Mount Sinai (New York, USA)coreTechnology or Integration · 1 March 2020Exclusive license for Mexico of rNDV (recombinant Newcastle Disease Virus) technology for COVID-19 vaccine development. Key scientists including Dr. Peter Palese, Dr. Florian Krammer, and Dr. Adolfo García-Sastre co-developed the technology. Avimex has collaborated with Mount Sinai on rNDV-based veterinary vaccines since 2003.
• University of Texas at AustincoreTechnology or Integration · 1 January 2020License agreement for the HexaPro (6 proline) spike protein technology for use in the Patria vaccine candidate.
• Government of Mexico (Gobierno Federal)flagshipStrategic or Co-development Partner · 1 January 2020The project was accompanied by President Andrés Manuel López Obrador and various federal government bodies to ensure continuity of support and integration into international cooperation frameworks under the Pentahelix innovation model. The Patria project represents a strategic priority for national vaccine sovereignty.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Elanco Animal Health: A global animal health leader formed from the Eli Lilly divestiture and Bayer Animal Health acquisition, with strong poultry, swine, and cattle health portfolios. Direct overlap with Avimex in livestock vaccines and pharmaceuticals, particularly in Latin American markets.
• Zoetis: The world's largest animal health company by revenue, offering a comprehensive portfolio of vaccines, pharmaceuticals, diagnostics, and feed additives across livestock and companion animals. Zoetis competes head-to-head with Avimex in poultry and swine vaccines across Latin America, but operates at vastly greater global scale.
• MSD Animal Health (Merck): Animal health division of Merck offering a broad portfolio of vaccines, anti-infectives, and parasiticides across livestock species. Comparable to Avimex in vaccine and antimicrobial product categories but with a global commercial footprint and substantially larger R&D budget.
• Boehringer Ingelheim Animal Health: A top-three global animal health player with a strong veterinary vaccines portfolio including swine and avian products. Directly comparable to Avimex's vaccine franchise but with much broader geographic reach and deeper R&D resources.

Direct peers

• Vetoquinol: A French animal health company focused on livestock and companion-animal pharmaceuticals and vaccines with strong Latin American distribution. Comparable in scale, geographic focus, and product categories to Avimex's core animal health business.
• Ceva Santé Animale: A privately held French multinational focused on animal vaccines, pharmaceuticals, and reproduction products with particularly strong poultry and swine portfolios in Latin America, Africa, and Asia. Closely comparable to Avimex in product mix, distributor-led GTM model, and emerging-market emphasis.
• Phibro Animal Health: A publicly traded animal health and nutrition company with comparable vaccines, anti-infectives, and mycotoxin-management products. Notably, Phibro already partners with Avimex as a distributor in Argentina, Uruguay, and Chile, signaling direct product and channel overlap.
• HIPRA: A Spanish veterinary pharmaceutical and vaccine company with a strong recombinant and vectorized vaccine portfolio in poultry and swine. Highly comparable to Avimex's Vaxigen platform approach and Latin American presence.

Emerging players

• Indian Immunologicals: A Hyderabad-based veterinary vaccine manufacturer producing animal and human vaccines at large scale for emerging markets. Comparable to Avimex in vector vaccine capabilities, government partnerships, and developing-market expansion strategy.

Regional players

• Bioveta: A Czech veterinary vaccine and pharmaceutical producer with strong Central/Eastern European roots exporting globally. Comparable in scale, private ownership structure, and broad livestock vaccine/pharma portfolio, though geographically complementary rather than overlapping with Avimex.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/avimexlab
• Facebookfacebook.com/AvimexLab

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Avimex